Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
all shares are volatile, but if you see long-term value you buy.... we will know more on long-term value in Septembers results release. And in terms of this morning, market makers probably spotted a load of stop-loss orders set at £7, which have now been robbed- classic
this really is way too volatile for a share that thinks it's worth £10+
40+ p swing in the first hour this morning on no news at all, and that's before any further movement is factored in for the day...... this is so unstable it's ridiculous
you're speculating that an offer like £10 per share would do it for a buy out... i'd take that in a heartbeat!
I wouldnt be happy with 10
Probably would be a take out bid right now
I remember something like that, however, i discounted it, because they have all been making some announcement about it, and to be honest, i don't think any of the companies fully know, until their figures are in, how they are going to be affected.
Am I mistaken or were we told a few weeks ago that the impact of COVID on Clinigen operations was minimal?
But tbh I think the market may have been expecting for companies like CLIN to be unaffected by the pandemic or even prosper.
Markets react to any news/updates immediately. We all know that in real life a considered response is more likely to be more proportionate/appropriate.
Quite a bounce today.....suggesting yesterday’s fall was an over reaction.
There were some cautious statements. If that is how the market treats companies that have still grown during the pandemic, then I would be v cautious about holding any shares over this results season....almost any share could see a 10-15% fall and then recover rapidly.
Think the drop has been overdone and taken the opportunity to top up at sub 680. As previously discussed, the Covid impact should only be short to medium term and am happy to look through that time frame.
Nd
... this pos wont even let me get an average down opportunity right.
much as a hate this share, the opportunity to drop £2 off my average should have been an opportunity not to pass up.... turns out there was another 20p (so far) that could have been saved per share.
oh well, on the brighter side, my average is now at least within the realms of possibility this year
So only a potential of ~90% upside.
Always take broker ratings with a pinch of salt
RBC cuts Clinigen price target to 1300 (1500) pence - 'OUTPERFORM'
This one was always going to suck. Plenty of positives, but market wont rebalanced this until full yr results in September, when we get a proper view on earnings. Revenue, profit, debt all positives, offset against an 'average' forecast... Good time to top up I think, but won't expect this to go anywhere but down/flat until September
Its difficult to fully digest the results until we benchmark with other industry competitors to see how everyone else performed in the current economic / Covid 19 environment.
Market reaction is prudent and the previous SP would not have taking into account much of a Covid 19 impact.
Market distinctly unimpressed
Agree
But this will come good
A disappointing reaction to what was a pretty decent update.
Probably a good buying opportunity.
Clinigen Group PLC (LON:CLIN) said the 2020 financial year was one of strong organic growth, though the headwinds from the coronavirus lockdown were felt in the final quarter.
In a trading update ahead of the pharma and services company’s September prelims, it said revenues are estimated to have grown by around 17% at constant currencies, or 13% on a gross reported basis for the year to June 30, 2020.
Analysts Clinigen follow closely as a benchmark gross profit, which the group said is expected to have advanced by at least 20% (both on a reported and constant currency basis), or 9% if you strip out the impact of acquisitions.
Underlying earnings (EBITDA), meanwhile, are forecast to have jumped by at least 29% year on year “with organic EBITDA growth ahead of organic gross profit growth”.
In the update, investors were told cash conversion returned to “normal levels” in the second half, with net debt of around £312mln at the period-end, or 2.3-times EBITDA.
Clinigen, which has its own line of specialist treatments as well as providing access to drugs not available in certain markets, reiterated its gross profit growth guidance of 5%-10% over the medium-term.
However, it cautioned that the financial year 2021 is likely to be at the lower end of that range as a result of coronavirus (COVID-19) disruption and the expected launch of a lower-cost ‘generic’ competitor to its antiviral Foscavir in the EU.
Clinigen said it expects the effect of COVID-19 will likely be felt into at least the first quarter of the new financial year. It estimates the financial impact to have been “at least £8mln to EBITDA” in the 12 months just gone, which was “primarily related to Proleukin”, the company’s cancer treatment.
"We continue to see organic growth in line with our medium-term guidance at this early stage of the new financial year, despite COVID-19 and expected competitive pressure to Foscavir,” Clinigen chief executive Shaun Chilton said in the statement
“As we look beyond the financial year 2021, we see growth significantly accelerating as we onboard new asset Erwinase and we continue to gain share in the end-markets we serve," he added.
When I saw the drug name, I Thought it was a new drug, but it is Proleukin.
If this Trial works, it represents a positive result and additional return supporting the investment in Refreshing this drug which I must admit to questioning due to its size relative to Clinigens market capitalisation. The board will be pleased with its decision.
End of July trading update ?
I honestly think there will be good results but will it push the sp up ?
I like to see my pharma stocks doing good in the world.
Orphan drug designation is an accelerator of value.....if the trials show a meaningful response.
It will be interesting to see the timetable for the Mirocals trial set out later this year. As the disease results in death between 2-4 years after diagnosis, treating cohorts of later stage and early stage patients should show results within 2 years.
That wasn’t a sell, it was the uncrossing trade (UT).
Ok A Mars bar and a Lucky Bag to make it more interesting.
I reckon update 16th July. Anyone fancy a Mars Bar on it?